Sharps Technology

Sharps Technology EBITDA Margin

The EBITDA Margin of Sharps Technology (STSS) as of Nov 2, 2026 is -132,210.43 %.

EBITDA Margin

-132,210.43 %

Last updated:

EBITDA Margin of Sharps Technology is 2025 -132,210.43 % . EBITDA Margin of Sharps Technology was 2024 - . It decreases by % lower compared to the previous year.

The Sharps Technology EBITDA Margin history

The Sharps Technology EBITDA Margin history
YEAREBITDA MarginYoY
-132,210.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sharps Technology Stock analysis

What does Sharps Technology do? Sharps Technology Inc. generates revenue through the development and manufacturing of innovative drug delivery systems, particularly its Sharps Provensa line of smart safety syringes. The company offers products like Sharps Provensa PS-3ML, Sharps Provensa RS-1ML, and Sharps Provensa PSU-0.3 ML, designed to address global healthcare challenges such as minimizing vaccine waste and providing needlestick protection. Its Ultra-Low Waste syringes are specifically marketed to healthcare providers and institutions seeking efficient solutions for vaccine administration. The firm also distributes Sharps Provensa RTF PS Glass Prefillable Syringes, targeting hospitals and clinics that require reliable, pre-filled syringe systems. The company's revenue streams are driven by the commercialization of its patented safety syringe technology, with a focus on healthcare facilities and organizations involved in vaccine distribution. Sharps Provensa PS-1ML and other models are positioned for use in clinical settings where safety and waste reduction are critical. The manufacturing facility, located over 160 kilometers from Budapest Airport, supports production for global distribution, though the business description does not specify exact buyer segments beyond healthcare providers. Safegard Medical, Inc., the wholly owned subsidiary, likely contributes to the company's product portfolio and manufacturing capabilities, though the business description does not detail its specific role in revenue generation. The firm's products are designed to meet the needs of healthcare systems aiming to reduce waste and improve safety, with no mention of additional revenue sources or partnerships beyond its core product lines. Sharps Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sharps Technology stock

EBITDA Margin of Sharps Technology is -132,210.43 % in 2025.

On Eulerpool you can find the complete historical development of EBITDA Margin Sharps Technology since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Sharps Technology with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sharps Technology

All Key Metrics — Sharps Technology